VBL Therapeutics Announces Enrollment of the First Patients in the Phase 2 Clinical Trial of VB-111 in Metastatic Colorectal Cancer
September 10, 2020 09:25 ET
|
VBL Therapeutics
Study to investigate for the first time a combination of VB-111 with the checkpoint inhibitor, nivolumab. TEL AVIV, Israel, Sept. 10, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT)...
VBL Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Proposed Clinical Development of VB-601
September 08, 2020 08:00 ET
|
VBL Therapeutics
Alignment with FDA on the path forward for the development of VB-601 TEL AVIV, Israel, Sept. 08, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) announced today the successful completion...
VBL Therapeutics Announces Second Quarter 2020 Financial Results and Provides Corporate Update
August 13, 2020 07:00 ET
|
VBL Therapeutics
●Positive data from the first interim analysis in the OVAL Phase 3 Potential Registration Study of VB-111 in Ovarian Cancer were presented at ASCO20; response rate in the VB-111 treatment arm was 58%...
VBL Therapeutics Announces Second Successful Pre-planned Interim Analysis with a Positive Data Safety Monitoring Committee Review Looking at OS - the Primary Endpoint of the OVAL Phase 3 Potential Registration Study of VB-111 in Ovarian Cancer
August 12, 2020 08:00 ET
|
VBL Therapeutics
TEL AVIV, Israel, Aug. 12, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) announced today that the independent Data Safety Monitoring Committee (DSMC) has completed its second, pre-planned...
VBL Therapeutics to Report Second Quarter 2020 Financial Results on August 13
August 03, 2020 08:00 ET
|
VBL Therapeutics
TEL AVIV, Israel, Aug. 03, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
VBL Therapeutics Presents MOSPD2 Bi-Specific Antibody Activity and Potential Survival Benefit for Solid Tumors in Late Breaking Research Session of the AACR Virtual Annual Meeting
June 22, 2020 08:00 ET
|
VBL Therapeutics
TEL AVIV, Israel, June 22, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today presented a late-breaking study showing that its proprietary MOSPD2 bi-specific antibody candidates induced...
VBL Presents New Data on the Potential of its Novel anti-MOSPD2 Monoclonal Antibodies for Rheumatoid Arthritis at the EULAR 2020 Congress
June 04, 2020 07:00 ET
|
VBL Therapeutics
TEL AVIV, Israel, June 04, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), (the “Company”) today announced new data implicating the potential of its proprietary anti-MOSPD2 antibodies for...
VBL Presents Positive Interim Data from the OVAL Phase 3 Pivotal Study in Ovarian Cancer at the ASCO20 Annual Meeting, Showing 58% or Higher Objective Response Rate
June 01, 2020 07:00 ET
|
VBL Therapeutics
OVAL independent Data Safety Monitoring Committee (DSMC) reviewed un-blinded data and determined that the study has met the interim pre-specified criterion of an absolute percentage advantage of 10%...
VBL Therapeutics to Present New Data on Its MOSPD2 Bispecific Antibody Program for Solid Tumors in Late Breaking Research Session of the AACR Virtual Annual Meeting
May 18, 2020 07:00 ET
|
VBL Therapeutics
TEL AVIV, Israel, May 18, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) announced today that new data suggesting the potential of its proprietary bi-specific antibodies for...
VBL Therapeutics Announces First Quarter 2020 Financial Results and Provides Corporate Update
May 14, 2020 07:00 ET
|
VBL Therapeutics
TEL AVIV, Israel, May 14, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced financial results for the first quarter ended March 31, 2020, and provided a corporate update. ...